To identify risk factors for further deterioration of central visual function in the eye with advanced glaucoma.

Patients with advanced glaucoma with well-controlled intraocular pressure (IOP), mean deviation (MD) of Humphrey Field Analyzer 242 Program (HFA 242) of 20 decibels or less, and visual acuity (BCVA) of 20/40 or more The HFA102 test and BCVA examination were performed every 6 months and the HFA 242 test every 12 months for 5 years. The Cox proportional hazards model was used to identify risk factors for deterioration of HFA102 and 242 results and BCVA. Deterioration of HFA 102 results was indicated by the presence of the same ≥3 points with a negative overall slope of 1 dB / year or less at P & lt. A result of 0.01 for 3 or more consecutive tests, a result of HFA 242 increases the score of Advanced Glaucoma Intervention Study (AGIS) by 2 or more in 2 or more consecutive tests, and a score of BCVA increases by 0.2 or more in log MAR. ≥ Two consecutive tests. A total of 175 eyes with progressive glaucoma from 175 patients (mean age 64.1 years; mean baseline IOP 13.2 mmHg; mean logMAR 0.02; mean HFA242 and 102MD, 25.9 and 22.9 decibels, respectively) were included.  The average IOP during the follow-up visit was 13.0 mmHg. The probabilities of worsening HFA 102 and 242 and BCVA results were 0.269 ± 0.043 (standard error), 0.173 ± 0.031, and 0.194 ± 0.033, respectively, after 5 years. A lower baseline BCVA (P = 0.012) was significantly associated with further deterioration of HFA102 results. Better HFA242MD (P & lt; 0.001) and use of systemic antihypertensive drugs (P = 0.009) were significantly associated with further deterioration of HFA242 results and a larger proportion of β-papillary atrophy / disc region (P & lt; 0.001). Was there Systemic antihypertensive drug use (P = 0.025) and lower BCVA (P = 0.042) were each significantly associated with further exacerbation of BCVA. In the eyes of progressive glaucoma with well-controlled IOP and BCVA, the β-papillary atrophy region/discretion ratio and the use of systemic antihypertensive drugs were important prognostic factors for further deterioration of central visual function.


 

Comments

Post a Comment

Popular posts from this blog

Independent and integrated ophthalmology – where justice and excellence meet

Image
About 2.2 billion people worldwide are visually impaired, at least half of whom are preventable. Current estimates of preventable causes of moderate to severe visual impairment or blindness include untreated refractive error (88.4 million), cataracts (94 million), glaucoma (7.7 million), corneal opacity (4.2 million), Includes diabetic glaucoma (3.9 million) and trachoma (3.9 million). 2 million), but mostly due to uncorrected presbyopia (826 million). Of gross domestic product.  The World Health Organization's resolution on "Integrated Human-Centered Ophthalmology (IPEC), Including Preventive Blindness and Visual Impairment". At the core of the resolution is to make IPEC the optimal model and ensure its widespread implementation. It is estimated that about two-thirds of the population of India may require free or subsidized eye care, and if they have no such access, they may suffer marginalization and exclusion. Affordable and accessible high-quality care delivered by t
Read more

A Revision of the International Classification of Retinopathy of Prematurity

Image
Retinopathy of prematurity (ROP) is still a major threat to premature babies' vision, with some cases resulting in irreversible vision loss. The International Categorization of Retinopathy of Prematurity (ICROP), a clinical classification system for acute ROP, was created in 1984 with input from experts from around the world.  Cryotherapy's efficacy in preventing retinal detachment and vision loss due to ROP was promptly proven in a multicenter clinical trial. 2 Since its inception, ICROP has enhanced clinical care by permitting reliable documenting of ROP, facilitating comparison of serial examinations by numerous doctors, and facilitating consultation with peers. The ICROP has undergone fine-tuning in the past, most recently in 2005. 3 The ICROP3 classification, which was released this year, was updated to better characterise the disease as it is being managed. 4 ICROP3's primary revisions address concepts added over the last two decades that are thought to influence the
Read more

Longitudinal Changes in Scotopic and Mesopic Macular Function as Assessed with Microperimetry in Patients with Stargardt Disease

Image
  The Nidek MP1S device was used to measure central 20 ° macular sensitivity under mesopic and scotopic conditions. Mean deviations (MD) from normal value for mesopic macular sensitivity for fovea (within 2 ° eccentricity) and extrafovea (4 ° 10 ° eccentricity) and the MD for scotopic sensitivity for extra fovea were calculated. Linear mixed effects models were used to estimate mesopic and scotopic changes and the mMD was 10.7 dB (p <0.001). Longitudinally, all eyes showed a statistically significant deterioration trend: the rates of foveal mMD and extrafoveal mMD and some were 0.72 (95% CI 0.37 to 1.07), 0.86 (95% CI: 0.58 to 1.14) and 1.12 (95% CI.). : 0.66 to 1.57) dB / year. In STGD1, the loss of scotopic macular function preceded the extrafovea and was faster than the loss of mesopic macular function. Scotopic and mesopic macular sensitivities using microperimetry provide alternative visual function results for STGD1 treatment studies. At baseline, all eyes had a larger sMD and
Read more